Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM - Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright also issued estimates for Rhythm Pharmaceuticals' Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Other equities analysts have also recently issued research reports about the company. JMP Securities restated a "market outperform" rating and issued a $75.00 price target on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Canaccord Genuity Group increased their target price on Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Needham & Company LLC increased their target price on shares of Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, March 18th. Jefferies Financial Group started coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They issued a "buy" rating and a $80.00 price objective on the stock. Finally, Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They issued an "outperform" rating and a $76.00 target price for the company. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, Rhythm Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $69.46.

Remove Ads

Rhythm Pharmaceuticals Price Performance

Shares of Rhythm Pharmaceuticals stock traded up $1.31 during trading on Monday, hitting $54.80. 416,136 shares of the stock were exchanged, compared to its average volume of 509,820. Rhythm Pharmaceuticals has a 12-month low of $35.17 and a 12-month high of $68.58. The stock has a market cap of $3.46 billion, a price-to-earnings ratio of -12.66 and a beta of 2.30. The firm's 50-day moving average price is $55.25 and its 200 day moving average price is $55.03.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The firm had revenue of $41.83 million for the quarter, compared to analysts' expectations of $38.48 million. As a group, research analysts forecast that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insiders Place Their Bets

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 1,678 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $99,723.54. Following the sale, the chief financial officer now owns 101,186 shares in the company, valued at $6,013,483.98. The trade was a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the transaction, the executive vice president now owns 40,370 shares of the company's stock, valued at approximately $2,078,247.60. This represents a 65.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 108,131 shares of company stock valued at $5,781,098 over the last 90 days. 5.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. boosted its position in Rhythm Pharmaceuticals by 1.9% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,416,952 shares of the company's stock valued at $126,624,000 after buying an additional 45,648 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Rhythm Pharmaceuticals by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,256,188 shares of the company's stock worth $65,824,000 after purchasing an additional 3,499 shares during the period. Janus Henderson Group PLC lifted its stake in Rhythm Pharmaceuticals by 103.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock valued at $68,309,000 after buying an additional 621,432 shares during the period. Alkeon Capital Management LLC lifted its stake in Rhythm Pharmaceuticals by 16.8% in the third quarter. Alkeon Capital Management LLC now owns 1,167,700 shares of the company's stock valued at $61,176,000 after buying an additional 167,700 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Rhythm Pharmaceuticals by 14.9% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,111,043 shares of the company's stock worth $58,208,000 after buying an additional 143,800 shares during the last quarter.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.